A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Recruiting

Phase 1

PF-08032562A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Sponsor:

Pfizer

Code:

NCT07318805

Conditions

Advanced Breast Cancer

Metastatic Breast Cancer (HR+/ HER2-)

Colorectal Cancer

Metastatic Colorectal Adenocarcinoma

Triple Negative Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

PF-08032562

Fulvestrant

Cetuximab

Fluorouracil

Oxaliplatin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-02-01. This information was provided to ClinicalTrials.gov by Pfizer on 2026-01-06.